
In the GEMSTONE-303 phase 3 trial, sugemalimab combined with chemotherapy significantly improved overall survival (15.6 vs 12.6 months) and progression-free survival (7.6 vs 6.1 months) in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5. The treatment showed a manageable safety profile, with grade 3+ adverse events occurring in 53.9% (sugemalimab) and 50.6% (placebo) of patients, respectively.
Like
Save
Share